These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 25174456

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F.
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary.
    Turashvili G, Grisham RN, Chiang S, DeLair DF, Park KJ, Soslow RA, Murali R.
    Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
    [Abstract] [Full Text] [Related]

  • 7. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
    Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IeM.
    J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D, Hirschmann A, Löhrs U, Diebold J.
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
    Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P.
    Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
    [Abstract] [Full Text] [Related]

  • 16. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM.
    Clin Cancer Res; 2004 Oct 01; 10(19):6432-6. PubMed ID: 15475429
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R, Kurman RJ, Logani S, Shih IeM.
    Am J Surg Pathol; 2007 Jul 01; 31(7):1007-12. PubMed ID: 17592266
    [Abstract] [Full Text] [Related]

  • 19. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
    Lasota J, Kowalik A, Wasag B, Wang ZF, Felisiak-Golabek A, Coates T, Kopczynski J, Gozdz S, Miettinen M.
    Am J Surg Pathol; 2014 Sep 01; 38(9):1235-41. PubMed ID: 24832158
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.